What is Biomarin Pharmaceutical Inc worth?
With the base-case assumptions below, a discounted cash flow model on Biomarin Pharmaceutical Inc's reported free cash flow gives $80.84 per share. The share price was $57.13 on November 10, 2026, 29% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 6.5% | 10.0% | $43.52 | -24% |
| Base | 11.5% | 9.0% | $80.84 | +42% |
| Bull | 16.5% | 8.0% | $155.23 | +172% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $109.24 | $118.02 | $128.75 | $142.16 | $159.41 |
| 8.0% | $87.97 | $93.66 | $100.39 | $108.46 | $118.33 |
| 9.0% | $72.46 | $76.35 | $80.84 | $86.08 | $92.28 |
| 10.0% | $60.68 | $63.45 | $66.59 | $70.17 | $74.31 |
| 11.0% | $51.45 | $53.47 | $55.74 | $58.29 | $61.19 |
Where the presets come from
Base: years 1 to 5 grow at Biomarin Pharmaceutical Inc's revenue growth rate over the last 5 fiscal years (11.6% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions